Russia To Roll Out COVID-19 Vaccine Based On Phase II Data
Study Of Just 76 Subjects Published In Lancet
You may also be interested in...
BioMarin’s Voxzogo, J&J’s cilta-cel and Takeda’s maribavir are among the novel agents with goal dates on US FDA’s November user fee calendar.
While AZ awaits an independent review, its CEO maintains the vaccine could soon be back on track for a late 2020/early 2021 approval.
The Indian regulator says it is not considering emergency use authorization for COVID-19 vaccines before completion of clinical trials, a stand validated by AstraZeneca halting trials of its vaccine candidate due to an adverse event in UK. Meanwhile, India has signed up for Phase III trials of Russia’s vaccine candidate